inotuzumab ozogamicin 0.9 MG Injection

Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.

Start free with Eleplan

Clinical drug

inotuzumab ozogamicin 0.9 MG Injection

0.9 MG · Injection · injection

A form of inotuzumab ozogamicin →

inotuzumab ozogamicin 0.9 MG Injection — CD22 (Clusters of Differentiation 22) inhibitors. Strength, form, class, interactions & more.

inotuzumab ozogamicin 0.9 MG Injection

Active ingredient

Classification

CD22 (Clusters of Differentiation 22) inhibitorsCD22-directed Immunoconjugate

Drug interactions

Concomitant use of BESPONSA with drugs that prolong the QT interval may increase the risk of QTc interval prolongation.

  • majordrugs that prolong the QT interval — increased risk of clinically significant QTc interval prolongation

Real-world adverse events (FAERS)

Death327Febrile Neutropenia254Venoocclusive Liver Disease253Off Label Use218Pyrexia186Neoplasm Progression155Acute Lymphocytic Leukaemia Recurrent143Thrombocytopenia141

Source: RxNorm + openFDA + RxClass + FAERS · 2026

Look up another medication

Powered by Eleplan

A drug lookup is just the start. Eleplan keeps the whole care plan in one place.

Medications, diagnoses, documents, appointments, and the whole care team — organized and always in sync, with Ellie, your AI care assistant, on top of it. Free to start.